Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants

Status Completed

Clinical Trial Summary

This protocol facilitates the development of methods for determining whether transplant recipients have developed immune hyporesponsiveness or tolerance towards their allograft. These methods will involve the study of peripheral blood or biopsy tissue obtained at regular intervals from patients receiving kidney or combined kidney-pancreas allografts at the Warren G. Magnuson Clinical Center. In addition, patients that have previously received a kidney or combined kidney-pancreas allograft will be evaluated using assays requiring peripheral blood mononuclear cells and/or biopsies. Assays developed under this protocol will be used in subsequent protocols to assess the effects of immune modulating treatment regimens and may eventually be used to direct clinical care or guide the withdrawal of immunosuppressive agents. However, patients enrolled in this protocol will not have any change in treatment based solely on the assays developed without being enrolled in an additional study.

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001858
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase
Start date	June 8, 1999
Completion date	May 30, 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02369354` - Transplant Social Worker Support for Live Kidney Donation in African Americans	N/A
Not yet recruiting	`NCT02225782` - Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function	Phase 4
Completed	`NCT00499187` - Fanconi Syndrome Due to ARVs in HIV-Infected Persons	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Withdrawn	`NCT00585429` - Evaluation of Kidney Disease in Liver Transplant Recipients	N/A
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Completed	`NCT00001835` - Oxaliplatin in Cancer Patients With Impaired Kidney Function	Phase 1
Completed	`NCT01331941` - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function	Phase 1
Terminated	`NCT00436748` - Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease	Phase 3
Completed	`NCT01467466` - Prevention of Serious Adverse Events Following Angiography	Phase 3
Completed	`NCT01235936` - Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia	Phase 2
Completed	`NCT01947829` - Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)	N/A
Completed	`NCT01974999` - A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT01228903` - Uric Acid and the Endothelium is CKD	N/A
Completed	`NCT00734357` - Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients	N/A
Completed	`NCT00781417` - Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	N/A
Completed	`NCT00094484` - Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis	Phase 3
Completed	`NCT00185159` - Olmesartan Medoxomil in Diabetes Mellitus	Phase 3
Completed	`NCT00093977` - Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.